University of Wolverhampton
Browse
Collection All
bullet
bullet
bullet
bullet
Listed communities
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

Wolverhampton Intellectual Repository and E-Theses > Research Institutes > Research Institute in Healthcare Science > Molecular Immunology Research Group  > The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.

Please use this identifier to cite or link to this item: http://hdl.handle.net/2436/14650
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!



Title: The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
Authors: Bates, Ruth L.
Payne, Sarah J.
Drury, S.L.
Nelson, Paul N.
Isenberg, D.A.
Murphy, John J.
Frampton, Geoffrey
Citation: Lupus 2003, 12(8): 617-622
Publisher: SAGE Publications
Issue Date: 2003
URI: http://hdl.handle.net/2436/14650
DOI: 10.1191/0961203303lu436oa
PubMed ID: 12945721
Additional Links: http://lup.sagepub.com/cgi/content/abstract/12/8/617
http://direct.bl.uk/bld/PlaceOrder.do?UIN=136076849&ETOC=RN&from=searchengine
Abstract: We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.
Type: Article
Language: en
Description: Metadata record only
Keywords: Systemic lupus erythematosus
Autoantigen
SLE
Anti-PAI-1
ISSN: 0961-2033
Appears in Collections: Molecular Immunology Research Group

Files in This Item:

There are no files associated with this item.



Related articles on PubMed
bullet
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus.
Shoenfeld Y, Szyper-Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A, Dayer JM, Roux-Lombard P, Fontao L, Kallenberg CG, Bijl M, Matthias T, Fraser A, Zandman-Goddard G, Blank M, Gilburd B, Meroni PL
2007 Jun
bullet
Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.
Caccavo D, Rigon A, Picardi A, Galluzzo S, Vadacca M, Ferri GM, Amoroso A, Afeltra A
2005 Aug
bullet
bullet
Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance.
Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G, Bollini B, Li Vecchi M
2005 Jun
bullet
See all 182 articles

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Fairtrade - Guarantees a better deal for Third World Producers

University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1LY

Course enquiries: 0800 953 3222, General enquiries: 01902 321000,
Email: enquiries@wlv.ac.uk | Freedom of Information | Disclaimer and copyright | Website feedback | The University as a charity

OR Logo Powered by Open Repository | Cookies